Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial

Peter B. Gilbert, David C. Montefiori, Adrian McDermott, Youyi Fong, View ORCID ProfileDavid Benkeser, Weiping Deng, Honghong Zhou, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Britta Flach, Bob C. Lin, Sarah O’Connell, Charlene McDanal, Amanda Eaton, Marcella Sarzotti-Kelsoe, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W. P. van der Laan, Nima Hejazi, Chuong Huynh, Jacqueline Miller, View ORCID ProfileHana M. El Sahly, Lindsey R. Baden, Mira Baron, Luis De La Cruz, Cynthia Gay, Spyros Kalams, Colleen F. Kelley, Mark Kutner, Michele P. Andrasik, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, View ORCID ProfileLindsay N. Carpp, Rolando Pajon, Dean Follmann, Ruben O. Donis, Richard A. Koup on behalf of the Immune Assays; Moderna, Inc.; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE); and United States Government (USG)/CoVPN Biostatistics Teams
doi: https://doi.org/10.1101/2021.08.09.21261290
Peter B. Gilbert
1The Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pgilbert@fredhutch.org
David C. Montefiori
4National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; the Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrian McDermott
2The Vaccine Research Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Youyi Fong
1The Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Benkeser
5The Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Benkeser
Weiping Deng
8Moderna, Inc., Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Honghong Zhou
8Moderna, Inc., Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher R. Houchens
6The Biomedical Advanced Research and Development Authority, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Martins
6The Biomedical Advanced Research and Development Authority, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lakshmi Jayashankar
6The Biomedical Advanced Research and Development Authority, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Flora Castellino
6The Biomedical Advanced Research and Development Authority, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Britta Flach
2The Vaccine Research Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bob C. Lin
2The Vaccine Research Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah O’Connell
2The Vaccine Research Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlene McDanal
4National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; the Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Eaton
4National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; the Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcella Sarzotti-Kelsoe
4National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; the Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yiwen Lu
1The Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chenchen Yu
1The Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bhavesh Borate
1The Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars W. P. van der Laan
1The Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nima Hejazi
7Graduate Group in Biostatistics, University ofBerkeley, Berkeley, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chuong Huynh
6The Biomedical Advanced Research and Development Authority, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqueline Miller
8Moderna, Inc., Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hana M. El Sahly
9Baylor College of Medicine, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hana M. El Sahly
Lindsey R. Baden
10Brigham and Women’s Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mira Baron
11Palm Beach Research Center, West Palm Beach, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis De La Cruz
12Keystone Vitalink Research, Greenville, SC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Gay
13University of North Carolina, Chapel Hill, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Spyros Kalams
14Vanderbilt University Medical Center, Nashville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colleen F. Kelley
15Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine and the Grady Health System, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Kutner
16Suncoast Research Group, Miami, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele P. Andrasik
1The Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James G. Kublin
1The Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Corey
1The Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen M. Neuzil
17The Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lindsay N. Carpp
1The Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lindsay N. Carpp
Rolando Pajon
8Moderna, Inc., Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dean Follmann
3The Biostatistics Research Branch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruben O. Donis
6The Biomedical Advanced Research and Development Authority, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard A. Koup
2The Vaccine Research Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background In the Coronavirus Efficacy (COVE) trial, estimated mRNA-1273 vaccine efficacy against coronavirus disease-19 (COVID-19) was 94%. SARS-CoV-2 antibody measurements were assessed as correlates of COVID-19 risk and as correlates of protection.

Methods Through case-cohort sampling, participants were selected for measurement of four serum antibody markers at Day 1 (first dose), Day 29 (second dose), and Day 57: IgG binding antibodies (bAbs) to Spike, bAbs to Spike receptor-binding domain (RBD), and 50% and 80% inhibitory dilution pseudovirus neutralizing antibody titers calibrated to the WHO International Standard (cID50 and cID80). Participants with no evidence of previous SARS-CoV-2 infection were included. Cox regression assessed in vaccine recipients the association of each Day 29 or 57 serologic marker with COVID-19 through 126 or 100 days of follow-up, respectively, adjusting for risk factors.

Results Day 57 Spike IgG, RBD IgG, cID50, and cID80 neutralization levels were each inversely correlated with risk of COVID-19: hazard ratios 0.66 (95% CI 0.50, 0.88; p=0.005); 0.57 (0.40, 0.82; p=0.002); 0.42 (0.27, 0.65; p<0.001); 0.35 (0.20, 0.61; p<0.001) per 10-fold increase in marker level, respectively, multiplicity adjusted P-values 0.003-0.010. Results were similar for Day 29 markers (multiplicity adjusted P-values <0.001-0.003). For vaccine recipients with Day 57 reciprocal cID50 neutralization titers that were undetectable (<2.42), 100, or 1000, respectively, cumulative incidence of COVID-19 through 100 days post Day 57 was 0.030 (0.010, 0.093), 0.0056 (0.0039, 0.0080), and 0.0023 (0.0013, 0.0036). For vaccine recipients at these titer levels, respectively, vaccine efficacy was 50.8% (−51.2, 83.0%), 90.7% (86.7, 93.6%), and 96.1% (94.0, 97.8%). Causal mediation analysis estimated that the proportion of vaccine efficacy mediated through Day 29 cID50 titer was 68.5% (58.5, 78.4%).

Conclusions Binding and neutralizing antibodies correlated with COVID-19 risk and vaccine efficacy and likely have utility in predicting mRNA-1273 vaccine efficacy against COVID-19.

Trial registration number COVE ClinicalTrials.gov number, NCT04470427

Competing Interest Statement

All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/downloads/coi_disclosure.docx and declare: P.B.G., D.C.M., Y.F., C.M., A.E., M.S.-K., Y.L., C.Y., B.B., L.v.d.L., H.M.E.S., L.R.B., M.B., C.F.K., L.C., and L.N.C. had support (in the form of grant payments to their institution) from the National Institutes of Health for the submitted work; R.A.K. had support (in the form of funds to the VRC to cover assay performance) from the National Institutes of Health for the submitted work; M.B., L.D.L.C., and C.F.K. had support (in the form of payments to their institution) from Moderna for the submitted work; W.D., H.Z., J.M., and R.P. are employed by Moderna Tx, Inc. and have stock and/or stock options in Moderna Tx, Inc.; L.R.B. declares support (in the form of grant payments to his institution) within the previous three years from the National Institutes of Health, the Wellcome Trust, and the Bill and Melinda Gates Foundation and has served on NIAID-NIH SMCs within the previous three years; M.B. declares support (in the form of grant payments to her institution) within the previous three years from the National Institutes of Health and the Centers for Disease Control; C.F.K. declares support (in the form of grant payments to her institution) within the previous three years from the National Institutes of Health, the Centers for Disease Control, Humanigen, Novavax, Viiv, and Gilead, as well as payments from Medscape and from Clinical Care Options within the previous three years for educational events; K.M.N. declares support (in the form of grant payments to her institution) within the previous three years from GSK, Pfizer, Bill & Melinda Gates Foundation, and PATH for vaccine research, as well as support (in the form of grant payments to her institution) within the previous three years from the National Institutes of Health for influenza vaccine research. All other authors declare no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, and no other relationships or activities that could appear to have influenced the submitted work.

Clinical Trial

COVE ClinicalTrials.gov number, NCT04470427

Funding Statement

Supported by Public Health Service Grant UM1 AI068635 to the HVTN Statistical Data and Management Center [SDMC], Fred Hutchinson Cancer Research Center [FHCRC] from the National Institute of Allergy and Infectious Diseases (NIAID) and by the Intramural Research Program of the NIAID. This work was also supported by Scientific Computing Infrastructure at Fred Hutch funded by ORIP grant S10OD028685. This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. 75A50120C00034, and Moderna, Inc.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The mRNA-1273-P301 study is being conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Good Clinical Practice guidelines, and applicable government regulations. The Central Institutional Review Board approved the mRNA-1273-P301 protocol and the consent forms. All participants provided written informed consent before enrollment. Central IRB services for the mRNA-1273-P301 study were provided by Advarra, Inc., 6100 Merriweather Dr., Suite 600, Columbia, MD 21044.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Address reprint requests to Dr. Gilbert at the Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA 98109-9024, pgilbert{at}fredhutch.org.

  • ↵¶ The members of the Immune Assays; Moderna, Inc.; CoVPN/COVE; and USG/CoVPN Biostatistics Teams are listed in the Supplementary Appendix.

  • - minor revisions to Supplementary Text 1 - minor revisions to paragraphs 4-6 of the Discussion - addition of two authors to the masthead

Data Availability

As the trial is ongoing, access to patient-level data and supporting clinical documents with qualified external researchers may be available upon request and subject to review once the trial is complete.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 15, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
Peter B. Gilbert, David C. Montefiori, Adrian McDermott, Youyi Fong, David Benkeser, Weiping Deng, Honghong Zhou, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Britta Flach, Bob C. Lin, Sarah O’Connell, Charlene McDanal, Amanda Eaton, Marcella Sarzotti-Kelsoe, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W. P. van der Laan, Nima Hejazi, Chuong Huynh, Jacqueline Miller, Hana M. El Sahly, Lindsey R. Baden, Mira Baron, Luis De La Cruz, Cynthia Gay, Spyros Kalams, Colleen F. Kelley, Mark Kutner, Michele P. Andrasik, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Lindsay N. Carpp, Rolando Pajon, Dean Follmann, Ruben O. Donis, Richard A. Koup
medRxiv 2021.08.09.21261290; doi: https://doi.org/10.1101/2021.08.09.21261290
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
Peter B. Gilbert, David C. Montefiori, Adrian McDermott, Youyi Fong, David Benkeser, Weiping Deng, Honghong Zhou, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Britta Flach, Bob C. Lin, Sarah O’Connell, Charlene McDanal, Amanda Eaton, Marcella Sarzotti-Kelsoe, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W. P. van der Laan, Nima Hejazi, Chuong Huynh, Jacqueline Miller, Hana M. El Sahly, Lindsey R. Baden, Mira Baron, Luis De La Cruz, Cynthia Gay, Spyros Kalams, Colleen F. Kelley, Mark Kutner, Michele P. Andrasik, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Lindsay N. Carpp, Rolando Pajon, Dean Follmann, Ruben O. Donis, Richard A. Koup
medRxiv 2021.08.09.21261290; doi: https://doi.org/10.1101/2021.08.09.21261290

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1264)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (538)
  • Epidemiology (10056)
  • Forensic Medicine (5)
  • Gastroenterology (502)
  • Genetic and Genomic Medicine (2486)
  • Geriatric Medicine (240)
  • Health Economics (482)
  • Health Informatics (1653)
  • Health Policy (757)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (538)
  • Infectious Diseases (except HIV/AIDS) (11896)
  • Intensive Care and Critical Care Medicine (627)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2304)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1259)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2295)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (657)
  • Rheumatology (289)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (273)
  • Toxicology (44)
  • Transplantation (131)
  • Urology (100)